Instructions for patients before use: in-depth analysis of pemetinib/pemetinib

Pemigatinib/Pemigatinib (Pemigatinib) is a bright star in the field of contemporary medicine, especially in the research and development of anti-cancer drugs. It is classified as a multikinase inhibitor, a drug that inhibits the activity of multiple kinases simultaneously, thus combating cancer progression at multiple levels. Cholangiocarcinomais a malignant tumor that is often diagnosed at an advanced stage. Due to its highly aggressive and elusive nature, treatment becomes extremely difficult. However, the emergence of pemetinib has opened up a new treatment avenue for such patients.

The anti-cancer mechanism of pemetinib mainly relies on the precise inhibition of Fibroblast Growth Factor Receptor (FGFR) family proteins. When FGFR proteins are abnormally active in tumor cells, they promote tumor growth and spread. Pemetinib is like a precise key, able to lock and inhibit these overactive proteins, thereby slowing or even stopping tumor progression.

What is more convenient is that pemetinib is administered orally, which undoubtedly improves patients' medication compliance and quality of life. But before starting this treatment, doctors do an important genetic test. This is because only those patients with cholangiocarcinoma associated with FGFR gene mutations are more likely to benefit from pemetinib treatment.

No drug can be completely free of side effects. Pemetinib may also cause some discomfort during use, such as fatigue, digestive system discomfort, high blood pressure, and hand-foot syndrome. Therefore, patients need to pay special attention to their physical condition during medication. If there are any abnormalities or discomforts, they should inform the doctor immediately so that the treatment plan can be adjusted in a timely manner.